Sharon Bio-Medicine Ltd has informed BSE that the company's active pharma ingredient (API) manufacturing plant at Taloja, Maharashtra, has been approved by European Directorate for the Quality of Medicines & Healthcare (EDQM) council of Europe for complying with the certificate of suitability, as well as the implementation of a suitable quality management system based on the Good Manufacturing Practice (GMP) as laid down in the EU Rules governing Medicinal Product in the European Union.
The EDOM approval is expected to further enhance Sharon Bio-Medicine’s sales in Europe and other countries in near future.
The EDOM approval is expected to further enhance Sharon Bio-Medicine’s sales in Europe and other countries in near future.